Antares Pharma (ATRS) operates in the injectable drug delivery market. According to a February 2017 report by MarketsandMarkets, the global injectable drug delivery market is expected to grow to $624.5 billion by 2021. This trend represents a CAGR[1. compound annual growth rate] of 11.5% from 2016 to 2021.
This growth in market size is expected on the back of label expansion or an increase in the number of diseases or patient types that the products target. This could result in an increase in the addressable patient population for these products.
The injectable drug delivery market is also expected to benefit from the multiple innovative products in the research and development (or R&D) phase.
Antares Pharma (ATRS) is a specialty pharmaceutical company focused on the development and commercialization of self-administered parenteral pharmaceutical products and technologies. The company develops and manufactures novel therapeutic products to enhance existing drug compounds and delivery methods.
Antares Pharma’s platforms for injection technology include Vibex, a pressure-assisted autoinjector. The company also makes reusable, needle-free injection devices that administer injectable drugs. These drugs are currently marketed through Ferring Pharmaceuticals and JCR, Antares Pharma’s partners, for use with human growth hormone.
In addition, Antares Pharma has two gel-based products commercialized by other partners under licensing agreements. The company receives royalties on sales of these products.
Analysts’ recommendations for Antares Pharma
Of the total five analysts covering Antares Pharma in November 2017, three gave it a “strong buy” rating, and two gave it a “buy” rating. There were no “sell” ratings.
The mean rating for Antares Pharma stock is 1.4, indicating a “strong buy” with a mean target price of $3.93. This rating indicates an upside of 119.0% over the current stock price of $1.80.
Antares comprises ~0.02% of the iShares Russell 2000 ETF’s (IWM) total portfolio holdings.
Of the six analysts covering Inogen (INGN), five gave it a “buy” or higher rating. Eight of the 11 analysts covering Intersect (XENT) gave it a “buy” or higher rating. Six of the seven analysts covering Orthofix (OFIX) gave the stock a “buy” or higher rating.
In the next part of this series, we’ll take a deeper look at Antares Pharma’s current business strategy.